Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Apomorphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 0.95 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.95 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | HPGD | P15428 | 8/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 6/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | PKM | P14618 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | G6PD | P11413 | 2/20 | 1.00 |
| ▸ | MPI | P34949 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apomorphine SCHEMBL21410343 | 1.00 | KDM4E (1.00) | KDM4EHPGDALDH1A1MAPTMAPK1 | |
| Apomorphine SCHEMBL21846961 | 1.00 | KDM4E (1.00) | KDM4EHPGDALDH1A1MAPTMAPK1 | |
| Apomorphine SCHEMBL30395698 | 1.00 | KDM4E (1.00) | KDM4EHPGDALDH1A1MAPTMAPK1 | |
| Apomorphine SCHEMBL1321033 | 1.00 | KDM4E (1.00) | KDM4EHPGDALDH1A1MAPTMAPK1 | |
| Apomorphine SCHEMBL4755216 | 1.00 | KDM4E (1.00) | KDM4EHPGDALDH1A1MAPTMAPK1 | |
| Apomorphine SCHEMBL29565637 | 1.00 | KDM4E (1.00) | KDM4EHPGDALDH1A1MAPTMAPK1 | |
| Apomorphine SCHEMBL232473 | 1.00 | KDM4E (1.00) | KDM4EHPGDALDH1A1MAPTMAPK1 | |
| Apomorphine SCHEMBL8524 | 0.99 | KDM4E (1.00) | KDM4EHPGDALDH1A1MAPTMAPK1 | |
| (S)Apomorphine SCHEMBL19469972 | 0.99 | KDM4E (1.00) | KDM4EHPGDALDH1A1MAPTMAPK1 | |
| Apomorphine SCHEMBL17870682 | 0.99 | KDM4E (0.98) | KDM4EHPGDALDH1A1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000910-A1 | METHOD FOR TREATING PARKINSON'S DISEASE THROUGH PHOTOSTIMULATION, AND DEVICE USED IN SAID METHOD | TSUBOTA LAB INC (JP) | 2026-01-01 | — | — | US | claimed |
| EP-4537896-A1 | METHOD FOR TREATING PARKINSON'S DISEASE THROUGH PHOTOSTIMULATION, AND DEVICE USED IN SAID METHOD | Juntendo Educational Foundation (JP) | 2025-04-16 | — | — | EP | claimed |
| CN-119343168-A | Method for treating parkinson's disease by light stimulation and device used in method | 学校法人顺天堂 | 2025-01-21 | — | — | CN | claimed |
| WO-2023238956-A1 | METHOD FOR TREATING PARKINSON'S DISEASE THROUGH PHOTOSTIMULATION, AND DEVICE USED IN SAID METHOD | 学校法人順天堂 | 2023-12-14 | — | — | WO | claimed |
| US-11459301-B2 | Crystalline form of s-apomorphine | ACLIPSE ONE, INC. (US) | 2022-10-04 | — | — | US | claimed |
| WO-2022185742-A1 | PROPHYLACTIC OR THERAPEUTIC COMPOSITION FOR DISSEMINATED INTRAVASCULAR COAGULATION SYNDROME | 学校法人埼玉医科大学 | 2022-09-09 | — | — | WO | claimed |
| EP-3793980-A1 | CRYSTALLINE FORM OF S-APOMORPHINE | Aclipse One, Inc. (US) | 2021-03-24 | — | — | EP | claimed |
| US-20260042746-A1 | 2(1H)-PYRIDINIMINE DERATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2026-02-12 | — | — | US | disclosed |
| US-20260000910-A1 | METHOD FOR TREATING PARKINSON'S DISEASE THROUGH PHOTOSTIMULATION, AND DEVICE USED IN SAID METHOD | TSUBOTA LAB INC (JP) | 2026-01-01 | — | — | US | disclosed |
| US-20250382282-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2025-12-18 | — | — | US | disclosed |
| US-12398125-B2 | Nitrogen-containing saturated heterocyclyl derivative | Sumitomo Pharma Co., Ltd. (JP) | 2025-08-26 | — | — | US | disclosed |
| EP-4563576-A1 | 2(1H)-PYRIDINIMINE DERATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2025-06-04 | — | — | EP | disclosed |
| EP-4563574-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC RING DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2025-06-04 | — | — | EP | disclosed |
| EP-3777858-A1 | AGENT FOR INHIBITING RISE IN INTRANEURONAL CALCIUM CONCENTRATION | Toray Industries, Inc. (JP) | 2021-02-17 | — | — | EP | disclosed |
| US-20210023068-A1 | AGENT FOR INHIBITING RISE IN INTRANEURONAL CALCIUM CONCENTRATION | TORAY INDUSTRIES, INC. (JP) | 2021-01-28 | — | — | US | disclosed |
| CN-111902143-A | Inhibitor for increase in intracellular calcium concentration | 东丽株式会社 | 2020-11-06 | — | — | CN | disclosed |
| WO-2020036231-A1 | DRUG MANAGEMENT METHOD FOR KIT FORMULATION REQUIRING DOSE ADJUSTMENT | レジメンキット株式会社 | 2020-02-20 | — | — | WO | disclosed |
| WO-2019189781-A1 | AGENT FOR INHIBITING RISE IN INTRANEURONAL CALCIUM CONCENTRATION | 東レ株式会社 | 2019-10-03 | — | — | WO | disclosed |
| US-20070071818-A1 | EFFERVESCENT FORMULATIONS COMPRISING APOMORPHINE | ARDANA BIOSCIENCE LIMITED (GB) | 2007-03-29 | — | — | US | disclosed |
| US-20060141032-A1 | Effervescent formulations comprising apomorphine | ARDANA BIOSCIENCE LIMITED (GB) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210023068-A1 | AGENT FOR INHIBITING RISE IN INTRANEURONAL CALCIUM CONCENTRATION | ITPR2, ATP2A2, ORAI1 | DRD2 2065/4885DRD3 2981/4885DRD4 3360/4885 |
| US-20260042746-A1 | 2(1H)-PYRIDINIMINE DERATIVE | PRNP, CLN6, CDR2 | DRD2 378/4885DRD3 762/4885DRD4 626/4885 |
| US-20250382282-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVE | H1-0, HTT, PRNP | DRD2 738/4885DRD3 1066/4885DRD4 722/4885 |
| US-11459301-B2 | Crystalline form of s-apomorphine | SRI, IAPP, SORT1 | DRD2 377/4885DRD3 436/4885DRD4 423/4885 |
| US-20260000910-A1 | METHOD FOR TREATING PARKINSON'S DISEASE THROUGH PHOTOSTIMULATION, AND DEVICE USED IN SAID METHOD | PARK7, SNCA, PMP22 | DRD2 71/4885DRD3 152/4885DRD4 113/4885 |
| US-12398125-B2 | Nitrogen-containing saturated heterocyclyl derivative | H1-0, HTT, PRNP | DRD2 738/4885DRD3 1066/4885DRD4 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.